Investigational drug · Phase 3
Nuvastatic 300
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fatigue Related to Cancer Treatment, Colon Cancer, Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Nuvastatic 300"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nuvastatic 300", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fatigue Related to Cancer Treatment
- Colon Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nuvastatic 300" as an intervention, largest first.
Natureceuticals Sdn BhdIndustry
NCT07669454 · 250 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 31, 2026
Drug: Nuvastatic 300; Placebo · For: Fatigue Related to Cancer Treatment; Colon Cancer
Sites: Visakhapatnam, India; Mysore, India; Jalgaon, India · 6 sites in all
- Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast CancerPivotal-lookingRecruiting
Natureceuticals Sdn BhdIndustry
NCT07669467 · 250 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 30, 2026
Drug: Nuvastatic 300; Placebo · For: Fatigue Related to Cancer Treatment; Breast Cancer
Sites: Visakhapatnam, India; Mysore, India; Jalgaon, India · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.